Related Experiment Video
Updated: Feb 22, 2026

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
Published on: December 23, 2014
Renin-Angiotensin System Inhibitors Can Prevent Intravenous Lipid Infusion-Induced Myocardial Microvascular
Takanori Yasu1, Akiko Mutoh2, Hiroshi Wada3
1Department of Cardiovascular Medicine & Nephrology, Dokkyo Medical University Nikko Medical Center.
Background:
Levels of triglycerides and free fatty acids (FFAs) are elevated in patients with diabetes and may contribute to endothelial dysfunction through renin-angiotensin system (RAS) activation and oxidative stress. The present study investigated how systemic FFA loading affected myocardial microcirculation during hyperemia via RAS.
Methods And Results:
Eight healthy men received candesartan, perindopril, or a placebo for 2 days in a double-blind crossover design, and then myocardial microcirculation during hyperemia induced by a 2-h infusion of lipid/heparin was assessed using dipyridamole stress-myocardial contrast echocardiography (MCE). Leukocyte activity and hemorheology were also assessed ex vivo using a microchannel flow analyzer, serum levels of oxidative stress markers, and IκB-α expression in mononuclear cells. Serum FFA elevation by the infusion of lipid/heparin significantly decreased myocardial capillary blood velocity and myocardial blood flow during hyperemia. Both candesartan and perindopril significantly prevented the FFA-induced decrease in capillary blood velocity and myocardial blood flow during hyperemia. Systemic FFA loading also caused an increase in the number of adherent leukocytes and prolonged the whole blood passage time. These effects were blocked completely by candesartan and partially by perindopril. Both agents prevented the FFA-induced enhancement of oxidative stress and IκB-α degradation in mononuclear cells.
Conclusions:
Both candesartan and perindopril can prevent FFA-induced myocardial microcirculatory dysfunction during hyperemia via modulation of leukocyte activation and microvascular endothelial function.
Insights
Elevated free fatty acids (FFAs) impair heart microcirculation. Angiotensin-converting enzyme inhibitors like candesartan and perindopril protect against this FFA-induced dysfunction by reducing oxidative stress and inflammation.
Area of Science:
- Cardiovascular Physiology
- Endocrinology
- Pharmacology
Background:
- Elevated triglycerides and free fatty acids (FFAs) are linked to endothelial dysfunction in diabetes.
- Renin-angiotensin system (RAS) activation and oxidative stress are potential mechanisms involved.
Purpose of the Study:
- To investigate the impact of systemic FFA loading on myocardial microcirculation during hyperemia.
- To determine the role of the RAS in FFA-induced microcirculatory changes.
Main Methods:
- Healthy men underwent a double-blind crossover study with candesartan, perindopril, or placebo.
- Myocardial microcirculation was assessed using dipyridamole stress-myocardial contrast echocardiography (MCE) after lipid/heparin infusion.
- Leukocyte activity, hemorheology, oxidative stress markers, and IκB-α expression were analyzed.
Main Results:
- Systemic FFA elevation reduced myocardial capillary blood velocity and blood flow during hyperemia.
- Both candesartan and perindopril prevented the FFA-induced decrease in myocardial blood flow.
- FFA loading increased leukocyte adhesion and prolonged blood passage time, effects blocked by candesartan and partially by perindopril.
- Both drugs mitigated FFA-induced oxidative stress and IκB-α degradation.
Conclusions:
- Candesartan and perindopril prevent FFA-induced myocardial microcirculatory dysfunction during hyperemia.
- These protective effects are mediated by modulating leukocyte activation and microvascular endothelial function.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Heart Failure Drugs: Diuretics
Acute Kidney Injury IV: Diagnostic Studies and Prevention

